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The graft-versus-tumor effect of DLI results from donor T-cell alloreactivity directed against recipient antigens, and correlates with GVHD development. Most patients with relapse after HSCT primarily need to receive conventional chemotherapy to reduce tumor burden before DLI. In HSCT patients exhibiting GVHD clinical manifestations at the time of relapse, the primary use of chemotherapy is quasi-constantly associated with donor T-cell alloreactivity reduction, as assessed by GVHD improvement or even disappearance. In contrast, GVHD elicitation by chemotherapy administration represents an unexpected event. We report such an unusual episode of acute GVHD occurring in an allo-transplanted patient after salvage chemotherapy of leukemia relapse using clofarabine, a second-generation purine analog that has proven efficacy in patients with relapsed leukemia. 3, 4 A 62-year-old woman underwent non-myeloablative HSCT from an HLA-matched sibling donor for Ph chromosome-negative B-cell precursor ALL. At transplant, the patient was in first CR obtained with clofarabine (30 mg/m 2 per day for 5 days) given after failure of three previous chemotherapy courses. The conditioning regimen consisted of fludarabine (90 mg/m 2 ), and a 2-Gy TBI and GVHD prophylaxis consisted in the association of CsA and mycophenolate mofetil. She did not develop any manifestation of GVHD so that CsA was disrupted at 3 months after HSCT. A few days after, she presented with massive medullar ALL infiltration. She received six weekly injections of vincristine (a 4-day course of dexamethasone was given together with the first four injections, but was further stopped because of osteoporotic vertebral fracture) without control of ALL. Then, the patient received clofarabine (30 mg/m 2 per day for 5 days) to reach CR and propose DLI. Unexpectedly, when recovering from aplasia, at day 25 after clofarabine, she developed a typical form of acute GVHD, with skin, digestive and liver involvement (Figure 1) . GVHD was histologically proven on skin biopsy. Thus, DLI was not administered, and the patient remains in CR, with chronic GVHD, at 9 months after HSCT. From day 40 after HSCT, as at time of relapse and also GVHD development, chimerism from PBMC and CD3 þ cells remained 495% donor, as determined by real-time quantitative PCR amplification of specific polymorphic sequences using a TaqMan technology (Applied Biosystems, Foster City, CA, USA).
We hypothesize that alloreactivity stimulation in this case may be the consequence of profound lymphopenia, induced by clofarabine. Indeed, such an induced lymphopenic environment can elicit T-cell expansion/activation, a phenomenon referred to as lymphopenia-induced proliferation and that can be distinguished from (allogeneic) antigen-induced proliferation. 5 This hypothesis is supported by the onset of GVHD at the precise time of hematological recovery following clofarabine course in our case (Figure 2 ). However, one cannot exclude that GVHD onset would be related to dexamethasone or even prior CsA disruption, although these two products were interrupted at 2 and 3 months before GVHD onset, respectively. This putative clofarabine-induced effect might be related to alloreactivity stimulation, obtained with the use of fludarabine, another purine analog. In patients who relapsed after HSCT, Miller et al. reported that lymphopenia induced in recipients by fludarabine combined with CY amplified the clinical manifestations of alloreactivity following DLI. This was demonstrated in a series of 15 patients receiving a fixed dose of 10 8 CD3 þ cells/kg immediately after the lymphodepleting treatment. In comparison with an historical cohort, lymphodepletion before DLI was associated with a significantly higher incidence of GVHD than after DLI alone. 6 DLI is routinely used for patients in relapse after HSCT, but is often unsuccessful in controlling malignancy. 1, 2 Improving the efficacy of DLI remains a major challenge for patients with few therapeutic options. Given that graftversus-tumor and graft-versus-host are linked effects of DLI, improving alloreactivity is a potential avenue for improving the graft-versus-tumor effect. Several factors, such as histocompatibility or sex mismatch between donor and recipient, as well as the CD3 þ T-cell dose infused, are classical determinants of alloreactivity. 7, 8 In clinical practice, some patients even exposed to these factors appear resistant to alloreactivity, as they never display any sign of GVHD after HSCT and DLI. In these cases, the adjunction of a supplementary T-cell stimulation by chemotherapyinduced lymphopenia might improve the efficacy of DLI. We suggest that clofarabine, in addition to its direct antitumoral effect, might be further explored with this aim to improve the strategies of allogeneic, and also autologous, 
